Cogent Biosciences (COGT) Osake Kurssi

Cogent Biosciences Inc is primarily active in the biotechnology industry.

The main competitors of Cogent Biosciences Inc in the market include large pharmaceutical companies such as Amgen, Inc., Gilead Sciences, Inc., and AbbVie Inc. These companies operate in the same biotechnology industry, striving to discover and develop innovative therapies for various diseases. Cogent Biosciences Inc competes with these industry leaders, focusing on advancing its proprietary precision medicine platform to target rare and genetically defined diseases. By leveraging its expertise and strategic collaborations, Cogent Biosciences Inc aims to differentiate itself and create valuable solutions in the highly competitive biotech market.

Cogent Biosciences Inc is a pharmaceutical company headquartered in Cambridge, Massachusetts. Established in 2015, the company focuses on developing precision therapies for genetically defined diseases. Cogent Biosciences primarily concentrates on discovering and developing drugs that target genetically driven forms of cancer. By leveraging its expertise in precision medicine and computational biology, the company aims to advance innovative treatments for patients in need. Cogent Biosciences Inc has established collaborations with leading academic institutions and industry partners to accelerate the development of its therapeutic candidates. With its commitment to scientific excellence, Cogent Biosciences Inc strives to transform the lives of patients by delivering breakthrough therapies for genetically driven diseases.

Some significant milestones achieved by Cogent Biosciences Inc include the successful completion of clinical trials for their lead drug candidate, CGT9486, which showed promising results in treating certain cancer types. The company also secured collaborations with renowned research institutions and pharmaceutical companies to further develop their pipeline. Cogent Biosciences Inc received FDA Fast Track designation for CGT9486, recognizing its potential as a breakthrough therapy. Furthermore, the company successfully raised funding through public offerings to support their research and development efforts. These achievements highlight Cogent Biosciences Inc's commitment to advancing innovative treatments in the field of biotechnology and their dedication to improving patient outcomes.

Cogent Biosciences Inc is primarily present in the United States.

Cogent Biosciences Inc represents a commitment to advancing the treatment options for patients with genetically-driven diseases. The company focuses on developing precision medicines that target the underlying causes of these diseases. Cogent Biosciences is driven by a patient-centric approach and values scientific innovation, collaboration, and patient advocacy. The company strives to make a meaningful impact on patients' lives by translating scientific discoveries into effective therapies. With its dedication to improving patient outcomes, Cogent Biosciences Inc aims to shape the future of precision medicine and contribute to the advancement of healthcare.

Analyytikot asettavat tällä hetkellä Cogent Biosciences-osakkeelle keskimääräisen tavoitehinnan 48,40 USD (mediaani: 52,00 USD), mikä merkitsee +68,4 % viimeisimpään hintaan verrattuna. Konsensus perustuu 18 analyytikkoarvioon.

Cogent Biosciences Analyytikkojen kursstavoitteet 2026

18 analyytikkoa arvioi tällä hetkellä Cogent Biosciences-osaketta: 16 suosittaa ostoa, 2 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Cogent Biosciences-yhtiöltä 5,98 M USD liikevaihtoa ja −3,41 USD osakekohtaista tulosta.

Cogent Biosciences Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Cogent Biosciences-osake noteerataan hintaan 25,68 EUR (28,74 USD).

Cogent Biosciences-osake (COGT) on listattuna 1 pörssissä, muun muassa: NASDAQ (COGT).

Cogent Biosciences Inc is a company specializing in the development of highly effective therapies for patients with serious immune system diseases and cancer. The company is headquartered in Cambridge, Massachusetts and was founded in 2015. Cogent Biosciences' business model is based on the development of therapies targeting critical signaling molecules in cellular signaling pathways that are critical in various types of cancer and autoimmune diseases. Cogent Biosciences plans to address the unmet medical need in these areas by developing innovative novel treatments using the unconventional approach of Doer-to-Drug Discovery. The company's research programs focus on identifying critical cellular signaling pathways that must be regulated in both cancer and autoimmune diseases. Cogent Biosciences has a proprietary screening platform that allows the company to quickly identify "druggable" targets and develop novel therapeutic agents. The company's platform is specifically designed to identify novel chemical compounds targeting cellular signaling pathways associated with cancer and autoimmune diseases. Cogent Biosciences relies on a partnering strategy that leverages the expertise and resources of large pharmaceutical companies to accelerate its clinical development programs. Cogent Biosciences focuses on clinical development programs in two key areas: cancer and autoimmune diseases. The focus of Cogent Biosciences' cancer programs is on the discovery of novel signaling pathways dysregulated in various tumor types. The company is working to develop effective clinical therapies targeting these unconventional signaling pathways. In the company's autoimmune research, Cogent Biosciences focuses on modulating immune-suppressed patient pathways and developing new innovative therapy approaches aimed at increased efficacy. Cogent Biosciences recently completed its Phase 1b study of the orally administered clinical candidate CGT9486, a first-in-class inhibitor targeting the BTK signaling target, which plays a significant role in many solid tumors. Also currently underway is a Phase 1b/2a study investigating the first-in-class inhibitor CGT378 in patients with EGFR cancer tumors. Cogent Biosciences is one of the newest pharmaceutical companies in the growth market and has shown successful investment in a few years with investors supporting the company. Cogent Biosciences expects its Doer-to-Drug Discovery approach to contribute to the long-term development of therapies that address the unmet medical need in both cancer and rheumatoid arthritis or lupus.

odotettu liikevaihto Cogent Biosciences on 5,98 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Cogent Biosciences on −230,28 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Cogent Biosciences:n hinta-voitto-suhde (P/E) on tällä hetkellä −8,44. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Cogent Biosciences-osakkeen arvostusta.

Cogent Biosciences:n hinta-myynti-suhde (P/S) on tällä hetkellä 324,82. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Cogent Biosciences-osakkeen arvostuskennuslukuna.

Cogent Biosciences:n Eulpool-laatuscore on 2/10.

Cogent Biosciences:n ISIN on US19240Q2012. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Cogent Biosciences:n WKN on A2QJAY. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Cogent Biosciences:n ticker on COGT. Tämä pörssinoteeraus käytetään Cogent Biosciences-osakkeiden kauppaan pörssissä.